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Abstract
Objective. Although cancer pain (consistent and
breakthrough pain [BTP; pain flares interrupting
well-controlled baseline pain]) is common among
cancer patients, its characteristics, etiology, and
impact on health-related quality of life (HRQOL)
across the lifespan are poorly understood.
Design. This longitudinal study examines age-
based differences and pain-related interference in
young and old patients with cancer-related pain over
6 months. Patients in the community with stage III or
IV breast, prostate, colorectal, or lung cancer, or
stage II–IV multiple myeloma with BTP completed
surveys (upon initial assessment, 3 and 6 months)
assessing consistent pain, BTP, depressed affect,
active coping ability, and HRQOL using previously
validated measures.
Results. Respondents (N = 96) were 70% white and
66% female, with a mean age of 57  10 years. There
were no significant differences in pain severity
based upon age. However, the younger group expe-
rienced more pain flares with greater frequency
(P = 0.05). The oldest group had better emotional
functioning at baseline but worse physical function-
ing at 6 months. Younger groups also had worse
cognitive functioning at 6 months (P = 0.03). Pain
interference was independent of age.
Conclusions. These data provide evidence for
the significant toll of cancer pain on overall health
and well-being of young and old adults alike but
demonstrate an increased toll for younger adults
(especially financially). Beyond race and gender dis-
parities, further health care disparities in the cancer
and cancer pain were identified by age, illustrating
the need for additional research across the lifespan
in diverse cancer survivors.
Key Words. Pain; Age-Based Differences and Dis-
parities; Quality of Care; Health-Related Quality of
Life; Physician Variability; Cancer
Introduction
Globally, both cancer and pain are significant public health
problems that are increasing in prevalence [1–5]. Despite
national efforts such as the Joint Commission on Accredi-
tation of Hospitals and Healthcare Organizations and the
Agency for Healthcare Research and Quality, and despite
global efforts such as the World Health Organization
and the International Association for the Study of Pain
designed to improve both cancer and pain care, nearly
70% of people dying from cancer experience unrelieved
pain [6–9]. Cancer pain, such as pain associated with
cancer or its treatment, exacts a significant individual and
societal toll and is increasing, especially among those with
advanced cancer [10–17]. Green and Montague showed
that cancer pain, including breakthrough pain (BTP), sig-
nificantly decreases health and quality of life (QOL; physi-
cal, social, and emotional health). As age is positively
associated with increasing comorbidities, it follows that
cancer, chronic pain, i.e., noncancer, nonmalignant, or
benign pain, lasting >6 months, and cancer pain will have
a greater impact on an aging U.S. population [18].
Unfortunately, the literature also suggests that the pain
complaints of the elderly, women, and minorities receive
less attention and treatment when compared with other
segments of the population [19]. Regardless of cancer
stage, racial or ethnic origin, gender, and age, when
pain accompanies cancer it significantly impacts health
and QOL [20]. The expected increases in the prevalence
of cancer and pain will yield increases in the potential
negative health sequelae associated with all types of pain,
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especially cancer pain. This is an important consideration,
as significant demographic changes are expected as
the baby boomers (i.e., those born between 1946 and
1964) age. By 2030, there will be an estimated 71.5 million
people >65 years old, 137 million minorities, and 185
million females in the United States [21–24]. A National
Institute on Aging exploratory workshop (6/2008) empha-
sized the critical need for research focusing on pain across
the lifespan [25]. Despite these efforts, the elderly, minori-
ties, and women continue to remain disadvantaged on
major health indices, and pain is a major threat to their
overall health [14,26–29].
All in all, pain assessment and treatment remains prob-
lematic despite the many therapeutic modalities available
to alleviate pain and suffering [30]. Both patient and phy-
sician factors contribute to variability in pain assessment
and treatment [31–35]. For instance, cancer patients may
be reluctant to discuss their pain complaints due to fears
that this conversation may distract their physician from
treating their cancer. They may also fear that pain is a sign
that the cancer is getting worse. In addition, Bernabei
et al. showed important clinician variability where older
minority patients with cancer were less likely to have their
pain score recorded [19]. Even when their pain score
was recorded, minorities received less pain medication
when compared with whites. Overall, minorities report
decreased access and less satisfaction with pain care
[31]. They are also more likely to receive suboptimal anal-
gesic therapy to manage their pain complaints when com-
pared with non-Hispanic whites [36]. Even when their pain
is assessed and treatment is prescribed, minorities and
low-income people experience additional barriers, with
pharmacies in minority neighborhoods less likely to main-
tain adequate opioid analgesic supplies than pharmacies
in predominantly white communities [37,38]. Few studies
have sought to examine age-based differences in patient
attitudes or physician treatment for cancer pain.
Both consistent pain and BTP (a transitory flare of mod-
erate to severe pain interrupting mild background pain that
is being controlled by a stable analgesic regimen such as
opioid analgesics) are common among cancer patients.
Their presence may indicate more severe pain syndromes
or an inadequate response to analgesic therapy [39–45].
Although most studies failed to report on potential varia-
tions in BTP [46–54], studies in advanced cancer by
Green and Montague revealed that minorities experience
more consistent pain and BTP while having decreased
QOL compared with whites. Moreover, although the lite-
rature reveals variability and differences in pain, cancer,
and cancer pain based upon both physician and patient
factors, it is unclear whether there are reductions in QOL
associated with pain, cancer, and cancer pain [32–34,55].
Also unclear is whether potential reductions in QOL asso-
ciated with pain, cancer, and cancer pain are similar
across the lifespan [56]. The cancer pain literature reveals
an association between pain and QOL. However, the
literature is relatively silent on age-based differences in
consistent and breakthrough cancer pain in racially and
ethnically diverse men and women. Thus, a prospective
6-month survey study was designed to 1) investigate
whether there are age-based differences in cancer pain
and 2) examine pain-related interference in young and old
adults with advanced cancer.
Methods
Participants and Recruitment
Institutional Review Board approval was obtained from the
University of Michigan Health System and four community
cancer clinics for this 6-month survey study. English-
speaking adults, 18–75 years, with stage III or IV breast,
colorectal, prostate, or lung cancer or stage II–IV multiple
myeloma from four community cancer clinics in Michigan
and the University of Michigan (UM) cancer registry, expe-
riencing BTP and receiving analgesics around the clock,
were identified by clinic or research staff. They were then
recruited to participate, face to face in the case of the four
clinics or by letter in the case of the registry. Age 75 years
was defined as the upper boundary based on the high
prevalence of pain from other sources in people greater
than 75 years old. Clinical and research staff identified
potential subjects for screening based on diagnosis, pain
medication status, and Eastern Cooperative Oncology
Group Performance Status of 2 (no more than 50%
of the day spent in bed) while those without pain or
not receiving pain medication were excluded. Upon enro-
llment, written informed consent was obtained. The
participants completed questions from a battery of well-
validated survey instruments upon initial assessment, 3
months, and 6 months. After recruitment, the sample was
stratified by age into three groups: 1) Group 1: 40 years;
2) Group 2: 41–59 years; and 3) Group 3: 60 years.
Measures
Validated survey instruments were given to each partici-
pant to assess pain characteristics, severity, and quality as
well as pain management attitudes, depression, active
coping skills, and QOL. Sociodemographic data such as
age, race, gender, marital status, education, employment,
and household income were also obtained. In addition,
cancer type, cancer stage, and comorbidities (using a
checklist of 19 different conditions using an instrument
adapted from Priccirillo et al. [57]) were also collected.
The Brief Pain Inventory (BPI) assessed pain characteris-
tics, severity, and interference with normal physical and
emotional functioning [58]. Both consistent pain and BTP
were assessed using four items: pain (least, average, right
now, and its worst in the past 24 hours) rated by pain
severity (0 = no pain; 10 = worst pain you can imagine).
A scale was calculated for each pain type from the mean
of the four items. The mean for seven other BPI items was
used to determine pain-related interference subscale
(0 = no interference; 10 = complete interference) for con-
sistent pain only. Internal reliability for the BPI Severity
subscale ranged a = 0.89–0.94 for consistent pain and
a = 0.83–0.87 for BTP, and for the BTP Interference sub-
scale ranged a = 0.93–0.95 for the three data waves. The
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BPI also includes items about pain characteristics (timing,
duration, quality, and cause), medication, pain medication
effectiveness, and an open-ended item regarding what
actions relieved pain. Pain characteristics, pain medica-
tion effectiveness (0–100%), and a dummy variable for
any activity effectively alleviating some portion of pain
(0 = nothing helps; 1 = something can be done to lessen
pain) were used for the analyses.
Current medications were collected and classified into
38 classes with near unanimous (99.5%) agreement
among knowledgeable health professionals. A distinction
was made in the question between consistent pain
medications, typically taken on a regular regimen, and BTP
medications, prescribed “as needed.” The 38 classes of
drugs were collapsed into four groups based on their
analgesic function with the strongest medication used by
the subject for pain relief classified to yield the drug potency
variable. The pain at worst score was collapsed into four
categories: 0 = absence of pain; 1 = mild pain; 2 = moder-
ate pain; and 3 = severe pain. The treatment analgesic
potency was combined with the patient’s severity scores at
worst during the past week to create the Pain Management
Index (PMI; the difference between the analgesic potency
and the categorized pain level [ranging from -3 and +3])
[59]. This ordinal variable was also used in its categorical
form with 0 = inadequate analgesic therapy (PMI = -3 to
-1) and 1 = adequate analgesic therapy (PMI = 0 to +3).
The Center for Epidemiological Studies Depression Scale
(CES-D) measured depressed affect. The four positively
worded items from the original 20-item survey were
dropped as factor analysis showed that the items did not
accurately predict negative affect when reversed, and a
literature review confirmed this in a cancer population
[60,61]. The ordinal values for the remaining 16 items were
summed and weighted to calculate an overall score com-
parable with the published scale range (0–60); scores >15
indicated severe psychological distress and depression.
Internal consistency for the 16-item CES-D ranged a =
0.81–0.92, consistent with published values [60], although
the 6-month reliability of 0.81 could be improved to 0.92 if
the item “everything I did was an effort” was dropped.
The John Henryism Active Coping Scale (JHACS) evalu-
ated active coping strategies at baseline. John Henryism is
a high output coping strategy characterized by protracted
struggles against seemingly insurmountable obstacles.
The construct was first reported among aging African
Americans and is correlated with hypertension and bodily
pain. The sum score of 12 Likert-type items was calculated
(1 = completely false; 5 = completely true; 60 = maximum
active coping score) with higher scores related to greater
use of high-effort coping. Internal consistency of the
JHACS was a = 0.87, higher than previously published
values [62]; as John Henryism is considered a trait, it was
only measured at baseline.
The Barriers Questionnaire (BQ-II) assessed barriers in
patient attitudes toward pain assessment and treatment.
The BQ-II questionnaire has four separate subscales:
physiological effects, fatalism, communication, and
harmful effects [63]. Mean scores were calculated for each
Likert-type subscale, and fatalism items were reverse
scored before analysis; higher scores were related to
greater endorsement for that type of barrier. The internal
consistency of BQ-II subscales ranged from a = 0.60–
0.91 for the three waves. Although the fatalism subscale
at baseline and communication barriers at 3 months had
a reliability value below previously published values [63], in
this sample, the reliabilities were above the threshold of
a = 0.60 and so were considered adequate. The small,
diverse sample and low number of questions on these
subscales may account for differences in reliabilities.
The European Organization for the Research and Treat-
ment of Cancer survey (EORTC QLQ-C30) assessed
health-related QOL [64]. Five QOL functioning domains
were assessed: physical, role, cognitive, emotional, and
social. In addition, eight symptom-control domains—
fatigue, pain, nausea and vomiting, dyspnea, anorexia,
diarrhea, and constipation—were evaluated for their con-
tribution to QOL. Each symptom control domain surveyed
patients for the frequency of a given symptom during the
past week. An additional measure assessed financial con-
cerns, and another measured global health and overall
QOL. Scores were linearly transformed to a 0–100 scale.
Internal consistency of the EORTC subscales ranged from
a = 0.71–0.91, higher than previously published results
[64].
Statistical Analysis
Descriptive statistics were calculated using SPSS 16.0.
Analysis of variance (ANOVA) and chi-square analysis were
used to determine differences between race, gender, and
age groups on sociodemographics, pain characteristics,
and experiences, and for each QOL measure examined.
ANOVA is relatively robust in terms of assumptions of nor-
mality. Repeated measures of ANOVA were then performed
to test whether consistent pain, BTP, depression, or QOL
changed significantly over waves, with least significance
difference tests performed post hoc to examine paired
comparisons. Repeated measures of ANOVA with age
group as a comparison (controlling by average pain) was
used to test whether changes over time differed by age
group. Finally, hierarchical regression was used to test
whether pain interference at baseline predicted QOL,
comorbidities, and coping at 6 months (although John
Henryism active coping was only available at baseline)
after controlling for age, race, and gender. In a final block,
a term for the interaction between age and interference




One hundred twenty-four participants provided written
informed consent. Thirty consenting participants died
prior to the study’s conclusion or within 6 months from
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original consent. Table 1 summarizes study retention over
the three waves of data collection. Nonwhites were more
likely than whites to decline after initial consent (21% vs
7%, P = 0.05). Participants who consented and then
declined most often responded that they were no longer
feeling well enough to complete their surveys. For the
sample completing the baseline survey (N = 96), 29%
were nonwhite (N = 28; 20 black, 4 Native American, 3
Hispanic, 2 Arabic, and 1 black/Native American). The
sample was primarily in the middle age group (41–59
years). The majority (66%) were women, and they were
aged from 57  10 years (mean  SD). More than one-
third of the sample reported difficulty paying for health
care; the youngest group reported significantly more diffi-
culty paying for health care than the older group. The
youngest age group had higher minority representation
and was less likely to fall in the highest-income group. The
most frequent morbidities for the group were arthritis or
rheumatism (42.7%), high blood pressure (37.5%), and
depression or anxiety (34.4%). Although Group 1 (younger
people) had significantly fewer comorbidities (F = 3.30,
P = 0.04) at study initiation, these differences disappeared
at 3 and 6 months (Figure 1). Employment differed by age
group but appears to be largely explained by high retire-
ment status among the oldest group. Additional demo-
graphic information is provided in Table 2 and can be
found in previously published studies [10,11].
Cancer Diagnosis
Breast cancer was the most common diagnosis (32%)
followed by lung cancer (28%), multiple myeloma (21%),
colorectal cancer (15%), and prostate cancer (3%). There
were no significant differences between whites and non-
whites in primary cancer diagnosis location or cancer
stage. Women were more likely to have breast cancer
(c2 = 44.2, P < 0.001). There are age group differences in
cancer diagnosis, particularly the relatively higher
frequency of breast and colorectal cancer in the youngest
group (P = 0.03). Table 2 provides additional sociodemo-
graphic information for the sample.
Pain Differences
Location
The most common pain locations were nonmidline back
(36%), spine (31%), and legs (28%). Although there were
no significant differences in the number of pain locations
at baseline, at 6 months, or at 3 months, there was a trend
toward the youngest group having more pain locations
(4.5 vs 2.3 and 2.2, P = 0.10). There were also a few
differences in pain prevalence at specific location. Pain in
low midline back, and arm at 3 months and shoulder pain
at 6 months are significantly more prevalent for the young-








Consented initially (N) 124 103 94 —
Surveys collected 96 (93%) 66 (81%) 46 (54%) —
Nonresponse/still consented (N) 7 15 39 —
Declined/left study (N) 12 8 3 0 23
































Figure 1 Consistent pain at worst and least by age group. Consistent pain (worst and least) in the last week
is measured on a 10-point scale (0 = no pain; 10 = worst pain imaginable) at baseline, 3 months, and 6
months. The participants were further categorized by their age (<40, 41–59, and 60 years). The figure
shows pain at worst dropped at trend level over time (P = 0.08).
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est group. Arm, shoulder, and abdominal pain at baseline
and spinal pain at 6 months were higher for the youngest
group at trend level. Spinal pain at baseline was more
common in the middle-age group at trend level.
Pain Severity and Treatment and Interference
There were no significant differences in consistent or BTP
levels at worst or least between the age groups. The
changes in the mean scores on the four consistent pain
measures over the study’s duration are shown in Figure 1.
The mean PMI of -1.01 suggests that most participants
were prescribed adequate pain medications (range = -3
to +3; negative numbers reflecting medication stronger
than pain strength and positive numbers reflecting pain
stronger than medication). When the PMI was examined
as a continuous variable, there were no age differences in
medication strength or subject-reported consistent pain
relief received from medication (62%, 56%, and 60% over
the three waves). Nor were there differences on examining
the dummy variable for “adequate” vs “inadequate” medi-
cation. However, pain interference was a significant issue
for participants. The mean interference at baseline ranged
from 3.6 for relationships to 5.5 for work (0 = no interfer-
ence; 10 = maximal interference). There was significantly
greater interference in mood and relationships for the
youngest group at baseline, although these differences
did not persist over time (Table 3).
BTP Characteristics
Although BTP history was required for study inclusion,
there was variability in BTP characteristics. On average,
participants experienced BTP for 619 days at baseline,
and BTP duration ranged from 0 to 168 months. There
were no age differences in BTP duration or length of
BTP episodes experienced on average per week, but the
youngest group experiences pain flares with significantly
greater frequency (62 vs 18 and 12, P = 0.05). Partici-
pants attributed the precipitating event for BTP to several
causes (e.g., movement, end of a course of pain medica-
tion). Although there was great variability within each
group, there were no significant differences in the ability
to predict BTP onset. Most subjects (79%) reported that
BTP could be at least partially palliated. The most
common method for relieving BTP was medications
(62%). There were no significant ethnic or gender differ-
ences in BTP placability, strategies, or effectiveness for
BTP relief. Figure 2 shows changes in BTP means over
the study course.
Comorbidities, Depression, Coping Strategies,
and QOL
Depression (via CES-D), coping strategies as defined by
the BQ-II and the JHACS, and QOL and symptoms as
measured by the EORTC are included in Table 3. The










Age range M  SD 56.8  10.1 35.2  5.2 52.8  4.7 66.1  4.2 244.5 (<0.001)
Race
% Nonwhite 29.2% 62.5% 24.0% 27.0% 5.08 (0.08)
Gender (% female) 62.9% 60.0% 68.3% 56.0% 1.82 (0.40)
Education 12.35 (0.14)
<12 years 14.6% 0.0% 16.0% 16.2%
High school 33.3% 0.0% 34.0% 40.5%
College 52.1% 50.0% 50.0% 43.2%
Marital status 61.7% 25.0% 62.5% 70.3% 19.45 (0.003)
Personal income
<$10,000 12.9% 25.0% 14.3% 8.6% 12.12 (0.06)
$10,000–30,000 34.4% 62.5% 22.4% 42.9%
$30,001–99,999 45.2% 0.0% 53.1% 45.7%
$100,000 7.5% 12.5% 10.2% 2.9%
Employed (% Y) 12.6% 20.0% 31.9% 8.6% 32.71 (<0.001)
Alive at 6 months (%) 75.8% 100.0% 71.4% 76.0% 3.83 (0.15)
Trouble paying for health care (%) 40.0% 75.0% 38.8% 35.1% 8.33 (0.08)
Comorbidities (%) 2.23  1.94 0.63  0.74 2.30  1.94 2.51  1.99 3.30 (0.04)
Cancer diagnosis
Breast 33.3% 50% 41.3% 20.0% 17.41 (0.03)
Colorectal 13.8% 40.0% 11.1% 12.0%
Lung 30.1% 0.0% 30.2% 36.0%
Multiple myeloma 17.9% 10.0% 14.3% 24.0%
Prostate 4.9% 0.0% 3.2% 8.0%
* c2 (df = 2) for percentages, F for group differences.
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subjects experienced significant psychological distress
and depression when measured with the CES-D (mean
baseline = 22.7  13.6; maximum score = 60 with scores
>16 indicating depression). The CES-D scores did not
have significant initial age differences. However, by 6
months, there were trend-level differences in the CESD,
with the younger group showing more depressive symp-
toms. The subscales of the BQ-II also did not differ by age,
with the exception of the youngest group having the
highest fatalism scores at 6 months (F = 3.33, P = 0.04).
All participants scored highly on the JHACS (mean = 47.6,
maximum score = 60), but scores did not differ by age.
Table 3 Differences by age group in pain variables over time
Group
Initiation 3 Months 6 Months
I II III P I II III P I II III P
Pain interference
General activity 6.67 4.62 4.47 0.29 4.00 4.14 4.66 0.73 3.86 4.00 4.69 0.55
Mood* 8.14 4.35 4.14 0.01 6.43 4.08 3.89 0.18 6.14 4.00 4.39 0.30
Walking ability* 6.57 3.96 4.49 0.17 4.43 3.84 5.23 0.19 4.57 3.86 5.42 0.12
Work (in and out of home) 6.71 5.11 5.74 0.43 5.67 4.54 5.71 0.31 5.83 4.63 5.83 0.27
Relationships 6.43 3.69 2.86 0.02 5.43 3.92 2.88 0.10 5.29 3.74 3.28 0.31
Sleep 7.14 5.08 5.46 0.30 4.29 4.86 4.71 0.90 3.71 4.60 4.94 0.64
Enjoyment of life 7.00 5.06 5.43 0.37 5.57 4.51 5.03 0.65 5.29 4.30 5.31 0.37
EORTC functioning
General health 43.8 55.4 49.8 0.37 44.8 56.5 51.4 0.30 45.8 55.9 48.6 0.25
Physical 67.5 63.1 54.3 0.17 69.2 62.5 52.5 0.11 62.5 63.2 49.3 0.05
Role* 47.9 46.9 46.2 0.99 50.0 51.3 43.8 0.55 35.4 52.4 41.9 0.19
Emotional 54.2 55.0 68.8 0.06 54.2 60.7 70.2 0.16 44.8 60.2 65.7 0.17
Cognition 60.4 63.7 68.6 0.61 50.0 63.0 67.6 0.21 43.8 62.3 69.9 0.03
Social 31.3 51.0 50.5 0.25 37.5 54.6 50.9 0.33 41.7 54.9 47.7 0.39
EORTC symptoms** 44.5 41.5 44.2 0.78 36.8 39.5 43.5 0.56 44.6 37.7 44.9 0.20
Barriers 1.92 1.73 2.05 0.46 2.28 1.58 1.88 0.20 2.32 1.58 1.98 0.12
Physiological 1.25 1.59 1.17 0.18 2.17 1.69 1.47 0.35 2.25 1.51 1.15 0.04
Fatalism** communication 1.23 1.10 1.16 0.94 1.00 0.87 1.02 0.80 1.15 0.95 1.22 0.53
Harmful effects 2.17 1.91 2.36 0.30 1.93 1.68 1.92 0.68 1.90 1.73 2.06 0.57
CES-D** 26.1 24.2 20.3 0.34 31.8 23.0 20.8 0.17 35.7 23.1 21.4 0.06
 Variables that change over time ( P < 0.05,  P < 0.10).
* Variable for which the slope of change is different by age group (** P < 0.05, * P < 0.10).





































Figure 2 Breakthrough pain (BTP) at worst and least by age group. BTP (worst and least) in the last week
is measured on a 10-point scale (0 = no pain; 10 = worst pain imaginable) at baseline, 3 months, and 6
months. The participants were further categorized by their age (<40, 41–59, and 60 years). The figure
shows no difference in pain at worst or least over time (P = 0.08).
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Regardless of age group, similarities were found on both
the EORTC, Functioning and Symptom Control Scales
(Figure 3). The oldest group tended to have better emo-
tional functioning at baseline (F = 2.95, P = 0.06) and had
significantly worse physical functioning at 6 months
(F = 3.08, P = 0.05) while the youngest group had signifi-
cantly worse cognitive functioning at 6 months (F = 3.80,
P = 0.03).
Interactions, Age over Time
Over time, there was a trend-level reduction in pain at its
worst (F[2,36] = 2.79, P = 0.08). Other measures did not
change. As summarized in Table 3, repeated measures
ANOVA with age group as a comparison and controlling for
the consistent pain mean found that emotional functioning
(EORTC) (F[2,81] = 5.92, P = 0.004) and depression
(CES-D) were worse over time (F[2,86] = 8.59, P < 0.001)
and CES-D changed differently by group (F[4,174] = 3.11,
P = 0.02), reducing for emotional functioning and increas-
ing for depression. At a trend level, physical functio-
ning (EORTC) (F[2,81] = 2.54, P = 0.09) and symptoms
(F[2,83] = 2.45, P = 0.09) both changed. Additionally, there
were three significant and four trend-level interactions
where the slope of change over time differed by age group.
Table 3 details change statistics over time and interactions
for the age groups.
Pain Interference and QOL, Comorbidities,
and Coping
QOL
Demographic variables had limited predictive power
related to QOL, with male gender predicting better general
health (b = 0.23, P = 0.04). Age predicts better emotional
(b = 0.23, P = 0.04) and cognitive (b = 0.24, P = 0.03)
functioning. Pain interference, however, played a much
stronger role, significantly predicting worse outcomes for
all six functioning scales and symptoms (P < 0.001). After
the entry of pain interference, race also becomes signifi-
cantly (b = 0.23, P = 0.03) associated with physical func-
tioning, where it was not at block of entry, suggesting that
were it not for pain interference, minority group members
would be physically functioning better than nonminorities.
There were no interactions between age and interfer-
ences, indicating that pain interference is independent of
age.
Comorbidities
Other than a trend for pain interference relating to more
comorbidities (b = 0.20, P = 0.08), there were no signifi-
cant relationships in this regression.
Coping
John Henryism active coping is higher for males at a trend
level (P = 0.08) and not related to any other variables.
Barriers to treatment, on the other hand, are higher for
racial minorities: communication and harmful effects sig-
nificantly, and physiological effects and fatalism at trend
level. When pain interference is added to the regression,
this significance disappears for all but harmful effects,
suggesting that the racial relationship for the other coping
styles is due to the greater pain interference. Finally, at a
trend level, all barriers but fatalism have interactions
between age and interference, such that older people with
more pain perceive greater barriers to pain treatment than
younger people or those with less interference.
Discussion
The prevalence of both cancer and pain is increasing.
















Figure 3 Functioning by age group via EORTC. The different subscales on the EORTC are shown by age
group at baseline. The figure shows that the oldest group tended to have better emotional functioning at
baseline (P = 0.06) and had significantly worse physical functioning at 6 months (P = 0.05) while the youngest
group had significantly worse cognitive functioning at 6 months (P = 0.03).
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ated with pain. Most cancer pain research has focused on
single cancer types or treatment modalities. Although dis-
parities in pain care based upon race, ethnicity, and
gender are well described, few studies have examined
age-based differences in consistent pain and BTP among
diverse populations [56,65,66]. Overall, we demonstrated
high consistent pain severity (with a slight reduction at its
worst over time) as well as high BTP severity over time.
Our previously published results identified important
ethnic disparities in cancer pain with nonwhites impacted
more than whites [10,11]. Although Portenoy brought
national attention to BTP’s impact on QOL, Green and
Montague provided important new insights into racial,
ethnic, and gender variations in BTP in our previous study
[10,11,41,65,67]. Older people are less likely to have their
pain assessed and treated and are at risk for increased
pain severity and the negative health outcomes associ-
ated with pain. However, to our knowledge, the literature
has not specifically examined age-based disparities in
cancer pain [14,19]. We did not identify any significant
differences in consistent pain or BTP at worst or least by
age group, although the youngest group did trend toward
a higher number of pain locations.
Overall, patient sociodemographic characteristics often
influence access and quality of pain care. In fact, the
literature consistently reveals an unequal burden of pain
and physician variability in pain management decision
making based upon social determinants [14,68]. For
instance, women have a higher prevalence for many
chronically painful syndromes than non-Hispanic whites
[14,69]. Women, minorities, and the elderly are also at risk
for suboptimal pain assessment and treatment. Thus, it
was not surprising for us to find that the younger group
had fewer (P < 0.05) comorbidities than the older group at
baseline. However, we were surprised to find that these
changes disappeared over time. It is plausible that this
may be due to survival effects. Patient preferences and
attitudes about cancer and pain may also play a significant
role in their willingness to report pain and to seek treat-
ment [31,36,70]. Thus, while the etiology remains unclear,
the ethnic and gender differences observed in this study
are consistent with our previous findings [10,68,69]. Phy-
sician variability in assessing and treating pain, as well as
structural barriers to accessing quality pain care, may lead
to suboptimal cancer pain management, thereby increas-
ing pain severity [35,37,71,72]. Future studies should
attempt to determine how patient age influences patient
preferences and attitudes about cancer pain management
in diverse populations across the lifespan.
Overall, the entire sample experienced clinically important
depressive symptoms and psychological distress. When
psychological impairment (via the CES-D) was examined,
no significant ethnic or gender differences were found.
Although there were no age differences at baseline and
depressive symptoms for all groups increased over time,
the slope significantly differed by age group with the
youngest group reporting increasing depressive symp-
toms over time more than the change in the other age
groups (reaching a trend-level difference by 6 months).
Younger people also reported significantly (P < 0.05) more
interference with their mood and relationships at baseline
(differences that disappeared over time), although the rela-
tionship slopes were not different by age. As observed in
our sample, the literature provides overwhelming evidence
for the high prevalence of depression in cancer and
chronic pain populations [73–76], although the exact
mechanism remains unclear. In addition, the literature
reveals increased depression and posttraumatic stress
disorder in minorities with chronic pain [31,69]. As both
groups were equally depressed, future studies should
attempt to disentangle cancer pain’s impact on emotional
health using structural equation modeling in an ethnically
diverse population across the life span.
Maladaptive coping strategies diminish QOL and the
ability to cope with significant illnesses. James et al. intro-
duced the concept of John Henryism and its strong asso-
ciation with African Americans [62]. We found John
Henryism was prevalent in the entire sample but did not
reveal racial or age differences. Attitudes and barriers to
care may influence access to care. We did not identify any
differences in the physiological, communication, or
harmful effects scales, by age group, but fatalism, except
at baseline, sloped differently by age group and was sig-
nificantly higher for the youngest group by 6 months.
All in all, this study provides many significant implications
for improving health and QOL in cancer patients.
However, there are potential limitations. First, the small
sample size used for data analysis may have limited the
potential-observed differences between groups, particu-
larly the small number in the <40 years of age group.
Related to this, the youngest sample was more likely to be
minority than the older two groups, and when considering
the small sample size for this group, there may be some
confounding of race and age issues. We believe that this
racial difference, however, may also indicate cancer dis-
parities, with minorities being more likely to get cancer
early and less likely to survive their cancer [15,16]. This is
also important, as those >75 years old were originally
excluded from the study, and our effects could have
potentially been more robust if this population was
included. The sample is potentially quite diverse with
respect to the length of time since cancer diagnosis, thus
making follow-up assessment more difficult to interpret.
Due to the unpredictable nature of cancer, participant
retention was difficult but comparable with other longitu-
dinal cancer studies [50]. Although differences in survival
rates were not significant by age group, it is plausible that
some changes over time might have been affected by
survival effect, with the healthiest surviving through all
three waves of data collection. Future studies should
attempt to increase the sample size to perform subgroup
analysis. Second, we used the last measured value of a
variable to allow for analysis, and this procedure may
minimize any changes that may happen over time. Third,
self-report and nonresponse bias must be considered,
although the surveys were completed privately and kept
confidential. Next, participating in this study may have
increased both patient and physician attention to pain,
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thereby enhancing pain care. As subjects were recruited
through cancer care facilities, our results may only reflect
those with access to care. Finally, outcome variables were
frequently correlated. Normally, this would be countered
by the use of a multivariate analysis technique, such as
MANCOVA, but in looking at the same measure over time,
we opted for repeated measures ANCOVA. This means that
results include a higher likelihood of type I error, due to
running multiple analyses.
In conclusion, to our knowledge, this is the first prospec-
tive study examining both consistent pain and BTP over
time in a diverse population across the life span. We
showed important and distinct differences in the impact of
cancer pain based upon the patient’s age over time. More
specifically, the youngest group initially had the greatest
pain interference but improved over time. They did not
look different mentally or emotionally at baseline, although
both cognitive functioning and depression worsened by 6
months. The oldest group at baseline had better emo-
tional functioning than the other two groups, but by 6
months has significantly worse physical functioning.
Overall, these results suggest that the youngest group is
having the most difficulty coping with cancer, pain, or both
in spite of potentially better survival odds. We also identi-
fied important financial difficulties for cancer patients,
especially for younger adults, with critically important
implications for health care and health policy.
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